BIO-TECHNE Corp
For the period ended Sep 30, 2025. Filed Nov 5, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 5, 2025
TECH$72.82-0.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Stockholders’ Equity
(in thousands)
| | | | | | | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| · · · · · · · · · · · · · Accumulated · · · | |||||||||||||||||
| · · · · · · · Additional · · · · · Other · · · | |||||||||||||||||
| · · Common Stock · · Paid-in · · Retained · · Comprehensive · · | |||||||||||||||||
| Three months ended September 30, 2025 · · Shares · · Amount · · Capital · · Earnings · · Loss · · Total | |||||||||||||||||
| Balances at June 30, 2025 | 154,972 | | $1,550 | | $911,089 | | $1,066,049 | | $(59,880) | | $1,918,808 | ||||||
| Net earnings | | | | | | | | 38,185 | | | | 38,185 | |||||
| Other comprehensive income | | | | | | | | | | (4,515) | | (4,515) | |||||
| Share repurchases | (1) | | | 0 | | | | (24) | | | | (24) | |||||
| Common stock issued for exercise of options | 625 | | | 6 | | | 21,477 | | | (5,895) | | | | 15,588 | |||
| Common stock issued for restricted stock awards | 110 | | | 1 | | | (1) | | | (3,337) | | | | (3,337) | |||
| Cash dividends ($0.08 per share) | | | | | | | | | | (12,444) | | | | (12,444) | |||
| Stock-based compensation expense | | | | | | | 11,543 | | | | | | | 11,543 | |||
| Common stock issued to employee stock purchase plan | 43 | | | 0 | | | 2,012 | | | | | | | 2,012 | |||
| Employee stock purchase plan expense | | | | | | | | (2) | | | | | | | | | (2) |
| Balances at September 30, 2025 | 155,749 | | $1,557 | | $946,118 | | $1,082,534 | | $(64,395) | | $1,965,814 | ||||||
| | | | | | | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| · · · · · · · · · · · · · Accumulated · · · | |||||||||||||||||
| · · · · · · · Additional · · · · · Other · · · | |||||||||||||||||
| · · Common Stock · · Paid-in · · Retained · · Comprehensive · · | |||||||||||||||||
| Three months ended September 30, 2024 · · Shares · · Amount · · Capital · · Earnings · · Loss · · Total | |||||||||||||||||
| Balances at June 30, 2024 | 158,216 | | $1,582 | | $820,337 | | $1,325,247 | | $(78,316) | | $2,068,850 | ||||||
| Net earnings | | | | | | | | 33,600 | | | | 33,600 | |||||
| Other comprehensive income | | | | | | | | | | 18,229 | | 18,229 | |||||
| Common stock issued for exercise of options | 577 | | 6 | | 23,224 | | (2,338) | | | | 20,892 | ||||||
| Common stock issued for restricted stock awards | 50 | | | 1 | | 1 | | (2,646) | | | | (2,644) | |||||
| Cash dividends ($0.08 per share) | | | | | | | | (12,688) | | | | (12,688) | |||||
| Stock-based compensation expense | | | | | 10,146 | | | | | | 10,146 | ||||||
| Common stock issued to employee stock purchase plan | 35 | | | 0 | | 2,227 | | | | | | 2,227 | |||||
| Employee stock purchase plan expense | | | | | | | | 38 | | | | | | | | | 38 |
| Balances at September 30, 2024 | 158,878 | | $1,589 | | $855,973 | | $1,341,175 | | $(60,087) | | $2,138,650 | ||||||
See Notes to the Condensed Consolidated Financial Statements.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.